Sun Pharma
Latest moves
Our read of each move first, where we have one; what the report said is marked Reported.
- Reported: Immediately quarantine the 11 recalled Sun Pharma eye-drug brands, secure substitute supply, and give pharmacists clear customer guidance to protect availability and trust.Reported: Sun Pharma has asked distributors to halt sales of 11 ophthalmic products after eye specialists flagged possible Pseudomonas contamination.Watch:
- Reported: Sun Pharma’s 16% growth in India formulations and 8.5% domestic market share signal sustained demand for pharmacy partners and strong availability of its branded portfolio.Reported: Sun Pharma reported Q1FY27 net profit of ₹2,894.79 crore, up 27% year on year, while revenue rose 10.46% to ₹15,299.88 crore. India formulations sales grew 16% to ₹5,475 crore, lifting domestic market share to 8.5%.Watch: Further movement in domestic market share above 8.5%, especially in chronic and specialty segments.
Background
From 4 stories, the newest dated 28 Sept 2026. Summary written 3 Oct 2026.
Sun Pharma is an Indian pharmaceutical company.
Show 3 more paragraphs and 4 sources
Its executives, alongside those of Cipla, Dr Reddy's and Lupin, said faster approvals, stronger trials infrastructure and domestic acceptance are needed to accelerate innovation. [1] source: Business Standard Sun Pharma says wider access to GLP-1 obesity and diabetes medicines could drive Indian pharma growth. [2] source: Business Standard
In September 2026, Sun Pharma secured exclusive rights to commercialise and manufacture lerodalcibep outside the US and China, targeting a $3.7 billion PCSK9 market. [3] source: Financial Express It will pursue regulatory approvals in territories where the cholesterol drug is not yet approved. [3] source: Financial Express Kotak projects India's GLP-1 obesity and diabetes drug market to reach Rs 15,700 crore by FY32, from Rs 4,000 crore in FY27, and identifies Sun Pharma as a likely beneficiary. [4] source: Financial Express The government plans to certify 1,000 clinical trial centres, the context in which Sun Pharma's executives made their call for regulatory reform. [1] source: Business Standard
Kotak names Lupin, Torrent, Eris, Alkem, Zydus and Mankind alongside Sun Pharma as likely beneficiaries of the GLP-1 market. [4] source: Financial Express
Sources
Questions about Sun Pharma
Who are Sun Pharma's main competitors?
Kotak named Sun Pharma alongside Lupin, Torrent, Eris, Alkem, Zydus and Mankind as likely beneficiaries of India's GLP-1 drug market in September 2026, and Sun Pharma, Cipla, Dr Reddy's and Lupin executives jointly urged faster approvals. [1] source: Business Standard[4] source: Financial Express
Stories that mention Sun Pharma
1 story
Sun Pharma is named in these stories but is not their subject.